Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM33 | Q9BZ11 | 9/20 | 0.79 |
| ▸ | MMP3 | P08254 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | ADAM17 | P78536 | 8/20 | 0.51 |
| ▸ | MMP1 | P03956 | 3/20 | 0.50 |
| ▸ | MMP13 | P45452 | 2/20 | 0.50 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP14 | P50281 | 1/20 | 0.50 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2680577 | 1.00 | ADAM33 (0.79) | ADAM33MMP3SMN1; SMN2ADAM17MMP1 | |
| SCHEMBL996481 | 0.91 | ADAM33 (0.84) | ADAM33MMP3SMN1; SMN2ADAM17MMP1 | |
| SCHEMBL996483 | 0.91 | ADAM33 (0.84) | ADAM33MMP3SMN1; SMN2ADAM17MMP1 | |
| SCHEMBL2680791 | 0.91 | ADAM33 (0.78) | ADAM33MMP3ADAM17MMP1MMP13 | |
| SCHEMBL2680798 | 0.91 | ADAM33 (0.78) | ADAM33MMP3ADAM17MMP1MMP13 | |
| SCHEMBL2681576 | 0.91 | ADAM33 (0.66) | ADAM33MMP3SMN1; SMN2ADAM17MMP13 | |
| SCHEMBL2681218 | 0.91 | ADAM33 (0.66) | ADAM33MMP3SMN1; SMN2ADAM17 | |
| SCHEMBL2680630 | 0.90 | ADAM33 (0.79) | ADAM33MMP3ADAM17MMP1MMP13 | |
| SCHEMBL2680625 | 0.90 | ADAM33 (0.79) | ADAM33MMP3ADAM17MMP1MMP13 | |
| SCHEMBL2681843 | 0.89 | ADAM33 (0.64) | ADAM33MMP3ADAM17ADAMTS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772478-B2 | Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-07-08 | — | — | US | disclosed |
| US-20120116072-A1 | NOVEL BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS | GALDERMA RESEARCH & DEVELOPEMENT (FR) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120116072-A1 | NOVEL BENZENESULFONAMIDE COMPOUNDS, METHOD FOR SYNTHESIZING SAME, AND USE THEREOF IN MEDICINE AS WELL AS IN COSMETICS | TYR, ARSA, STS | ADAM33 3905/4885MMP3 3872/4885SMN1; SMN2 3276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.